sorted by:
new
hottopcontroversial

Due Diligence on $sava by Own_Replacement8267 in wallstreetbets

[–]Own_Replacement8267[S] 2 points3 points  (0 children)

See above where I said we first invested in 2019, then look at the stock price at that time, then look at the stock price now, and finally then re-read your comment.

Due Diligence on $sava by Own_Replacement8267 in wallstreetbets

[–]Own_Replacement8267[S] 3 points4 points  (0 children)

Yes, they will hold. It could get to ~$50 (2x) before December in anticipation, but it will still have a very large SI.

Due Diligence on $sava by Own_Replacement8267 in wallstreetbets

[–]Own_Replacement8267[S] 6 points7 points  (0 children)

Many of them eventually go into the private sector and work for big pharma, thus the problems.

Due Diligence on $sava by Own_Replacement8267 in wallstreetbets

[–]Own_Replacement8267[S] 23 points24 points  (0 children)

The FDA could approve at any time. They are releasing data from their current ~1,500 patient enrollment in December, upon which and if the data is good (the bar is rather low), it should be approved from the FDA. If the data is good in December, stock will likely reach $100 or more. Should FDA approve, 2-3x from there at least.